Laird Norton Wetherby Wealth Management LLC Sells 1,904 Shares of Abbott Laboratories (NYSE:ABT)

Laird Norton Wetherby Wealth Management LLC lessened its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 3.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 55,488 shares of the healthcare product maker's stock after selling 1,904 shares during the period. Laird Norton Wetherby Wealth Management LLC's holdings in Abbott Laboratories were worth $6,276,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Redwood Park Advisors LLC bought a new stake in Abbott Laboratories during the fourth quarter worth approximately $25,000. Noble Wealth Management PBC acquired a new position in shares of Abbott Laboratories during the 4th quarter valued at $26,000. NewSquare Capital LLC raised its stake in shares of Abbott Laboratories by 78.4% in the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker's stock worth $27,000 after buying an additional 105 shares in the last quarter. WealthTrak Capital Management LLC acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at $28,000. Finally, Rialto Wealth Management LLC acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at $29,000. Institutional investors own 75.18% of the company's stock.

Analysts Set New Price Targets

ABT has been the topic of several research reports. Argus upgraded shares of Abbott Laboratories to a "strong-buy" rating in a research report on Tuesday, January 28th. Morgan Stanley boosted their target price on shares of Abbott Laboratories from $117.00 to $127.00 and gave the stock an "equal weight" rating in a report on Thursday, April 17th. Bank of America raised their target price on shares of Abbott Laboratories from $133.00 to $150.00 and gave the stock a "buy" rating in a report on Monday, March 10th. Barclays lifted their price target on shares of Abbott Laboratories from $158.00 to $159.00 and gave the stock an "overweight" rating in a research report on Thursday, April 17th. Finally, Jefferies Financial Group increased their price objective on Abbott Laboratories from $135.00 to $137.00 and gave the company a "hold" rating in a research report on Thursday, April 17th. Four investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and an average target price of $142.59.

Abbott Laboratories Trading Up 3.8%

Abbott Laboratories stock traded up $4.83 during mid-day trading on Thursday, hitting $133.39. The stock had a trading volume of 8,402,833 shares, compared to its average volume of 6,124,532. The stock has a market capitalization of $232.08 billion, a PE ratio of 17.44, a P/E/G ratio of 2.52 and a beta of 0.74. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $141.23. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. The stock has a 50-day simple moving average of $129.39 and a two-hundred day simple moving average of $123.75.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.07 by $0.02. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.38 billion. As a group, sell-side analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be paid a dividend of $0.59 per share. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.77%. Abbott Laboratories's dividend payout ratio (DPR) is presently 30.61%.

Insider Buying and Selling at Abbott Laboratories

In related news, Director Sally E. Blount sold 2,600 shares of the stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total transaction of $337,116.00. Following the completion of the sale, the director now directly owns 34,058 shares of the company's stock, valued at approximately $4,415,960.28. This represents a 7.09% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Eric Shroff sold 562 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $138.17, for a total value of $77,651.54. Following the transaction, the senior vice president now owns 31,970 shares of the company's stock, valued at approximately $4,417,294.90. This trade represents a 1.73% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 95,278 shares of company stock valued at $12,745,859. 0.46% of the stock is currently owned by company insiders.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.